(NASDAQ: BPMC) Blueprint Medicines's forecast annual revenue growth rate of 27.98% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.91%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.44%.
Blueprint Medicines's revenue in 2024 is $434,414,000.On average, 9 Wall Street analysts forecast BPMC's revenue for 2024 to be $32,148,901,992, with the lowest BPMC revenue forecast at $30,245,921,989, and the highest BPMC revenue forecast at $33,203,049,747. On average, 9 Wall Street analysts forecast BPMC's revenue for 2025 to be $43,954,543,726, with the lowest BPMC revenue forecast at $38,814,922,276, and the highest BPMC revenue forecast at $47,777,782,760.
In 2026, BPMC is forecast to generate $58,266,216,243 in revenue, with the lowest revenue forecast at $50,701,877,083 and the highest revenue forecast at $67,407,266,702.